Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Investigator: Jun Zhang, MD

Study Coordinator: Gabrielle Hayes

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT02193282

Phone: 734.419.948

Protocol Number: Pro00012699


This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
More to Explore